Xiuyi Pan

572 citations
17 papers · 132 indexed · h-index 6
Topics
Renal cell carcinoma treatment (6 papers)Epigenetics and DNA Methylation (5 papers)Renal and related cancers (5 papers)
Partner nations
ChinaGermanyOman

In The Last Decade

Xiuyi Pan

15 papers receiving 131 citations

Peers

Xiuyi Pan
Comparison fields: 5 of 27
  • Pulmonary and Respiratory Medicine 90
  • Molecular Biology 68
  • Cancer Research 38
  • Urology 33
  • Rheumatology 24
Replace Mahmut Akgül with:
Mahmut Akgül United States
Morgan Rouprêt France
Benkang Shi China
Bijun Lian China
Jin Ye-ning China
Marios Marcou Germany
Victor Kucherov United States
Holly Ní Raghallaigh United Kingdom
Jens R. Laurberg Denmark
Pradeep Bose United Kingdom
Xiuyi Pan relative to Mahmut Akgül United States Mahmut Akgül's profile →
Citations per field
00.5×10×17×
Mahmut Akgül · 1×
Citations per year

Countries citing papers authored by Xiuyi Pan

Since Specialization
Citations

This map shows the geographic impact of Xiuyi Pan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiuyi Pan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiuyi Pan more than expected).

Fields of papers citing papers by Xiuyi Pan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiuyi Pan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiuyi Pan. The network helps show where Xiuyi Pan may publish in the future.

Co-authorship network of co-authors of Xiuyi Pan

This figure shows the co-authorship network connecting the top 25 collaborators of Xiuyi Pan. A scholar is included among the top collaborators of Xiuyi Pan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiuyi Pan. Xiuyi Pan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
#WorkIndexed citations
1 0
2 1
3 0
4 2
5 1
6 4
7 16
8 2
9 2
10 1
11 4
12 21
13 9
14 11
15
[Prognostic Significance of ERG Gene Rearrangement and Protein Expression in Prostate Cancer].
2
16 37
17 19

About Xiuyi Pan

Xiuyi Pan is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Molecular Biology, having authored 17 papers that have together received 132 indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (6 papers), Epigenetics and DNA Methylation (5 papers) and Renal and related cancers (5 papers). The work is most often cited by research in Urology (33 citations), Pulmonary and Respiratory Medicine (90 citations) and Cancer Research (38 citations). Xiuyi Pan has collaborated with scholars based in China, Germany and Oman. Frequent co-authors include Ni Chen, Qiao Zhou, Mengni Zhang, Xiaoxue Yin, Xingming Zhang, Hao Zeng, Pengfei Shen, Miao Xu, Ling Nie and Xueqin Chen. Their work appears in journals such as Scientific Reports, British Journal of Cancer and The American Journal of Surgical Pathology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026